Goelzer Investment Management Inc. Cuts Holdings in IQVIA Holdings Inc. $IQV

Goelzer Investment Management Inc. reduced its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 75.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,713 shares of the medical research company’s stock after selling 14,598 shares during the quarter. Goelzer Investment Management Inc.’s holdings in IQVIA were worth $895,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of IQV. Asset Dedication LLC grew its holdings in IQVIA by 224.0% in the second quarter. Asset Dedication LLC now owns 243 shares of the medical research company’s stock valued at $38,000 after purchasing an additional 168 shares during the period. Trust Co. of Toledo NA OH purchased a new position in shares of IQVIA during the 2nd quarter valued at approximately $39,000. J.Safra Asset Management Corp grew its stake in IQVIA by 208.6% in the 2nd quarter. J.Safra Asset Management Corp now owns 250 shares of the medical research company’s stock valued at $39,000 after acquiring an additional 169 shares during the period. Rothschild Investment LLC raised its position in IQVIA by 85.5% during the second quarter. Rothschild Investment LLC now owns 269 shares of the medical research company’s stock worth $42,000 after acquiring an additional 124 shares during the period. Finally, NewSquare Capital LLC lifted its holdings in IQVIA by 185.3% during the second quarter. NewSquare Capital LLC now owns 291 shares of the medical research company’s stock valued at $46,000 after purchasing an additional 189 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Performance

NYSE IQV opened at $224.44 on Tuesday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.70 and a current ratio of 0.70. The stock’s fifty day moving average is $219.47 and its two-hundred day moving average is $193.38. The firm has a market capitalization of $38.22 billion, a P/E ratio of 30.79, a price-to-earnings-growth ratio of 2.47 and a beta of 1.37. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $234.29.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 EPS for the quarter, topping the consensus estimate of $2.98 by $0.02. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The business had revenue of $4.10 billion for the quarter, compared to analyst estimates of $4.07 billion. During the same quarter in the previous year, the firm earned $2.84 EPS. The company’s quarterly revenue was up 5.2% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. On average, research analysts anticipate that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on IQV. Barclays set a $230.00 target price on shares of IQVIA in a research note on Monday, December 15th. Weiss Ratings reissued a “hold (c)” rating on shares of IQVIA in a report on Wednesday, October 8th. Robert W. Baird set a $258.00 price target on IQVIA and gave the stock an “outperform” rating in a research note on Wednesday, October 29th. Jefferies Financial Group raised IQVIA from a “hold” rating to a “buy” rating and increased their price objective for the company from $195.00 to $225.00 in a research note on Tuesday, September 9th. Finally, JPMorgan Chase & Co. lifted their target price on shares of IQVIA from $177.00 to $255.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 29th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, IQVIA presently has an average rating of “Moderate Buy” and a consensus price target of $243.19.

Insiders Place Their Bets

In other news, insider Eric Sherbet sold 4,000 shares of the stock in a transaction that occurred on Wednesday, October 29th. The shares were sold at an average price of $219.70, for a total value of $878,800.00. Following the completion of the sale, the insider owned 27,108 shares of the company’s stock, valued at $5,955,627.60. This represents a 12.86% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 1.60% of the stock is owned by insiders.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.